Monrovia's Xencor Loses Less Money Than Anticipated - Stock Moves Up

Monrovia's biotech firm, Xencor, which is developing antibodies for autoimmune diseases and cancer, reported a second quarter loss of $16 million, or $0.30 per share, but its stock closed higher because the loss was less than anticipated. https://is.gd/21wyA6

- Brad Haugaard